ClinicalTrials.gg
RecruitingNCT07070323nanobody CD5Updated Nov 26, 2025

A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies

A Phase 1/2 interventional study of Autologous CD5 CAR T-cells and Previous stem-cell transplantation (SCT) donor-derived CD5 CAR T-cells in T-Cell Acute Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, in Relapse and Refractory Acute Lymphoblastic Leukemia, sponsored by Beijing GoBroad Hospital. Recruiting at 4 sites in China. Open to participants aged 1 Year to 70 Years. Per ClinicalTrials.gov, last updated 2025-11-26.

Sponsored by Beijing GoBroad Hospital · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
54
Allocation
Non-randomized
Ages
1 Year to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 51 studies in Precursor T-Cell Lymphoblastic Leukemia-Lymphoma with a site in China — 27 open to participants now, 28 under way, 4 of them phase 3. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma · China.

Planned enrollment
12th of 50
54 · median 30
Started
2025
with 7 others
Phase 1/2
11 of 51
8 open now
Primary completion
2026-12
later than 11 of 27 live
Registered
46th of 51
by date
Lead sponsor
3 of 51
Beijing GoBroad Hospital

Among the 51 studies in Precursor T-Cell Lymphoblastic Leukemia-Lymphoma with a site in China, this one is the 12th largest by planned enrollment of the 50 interventional ones that give a count, is one of 8 that started in 2025, is one of 11 in phase 1/2, reaches primary completion later than 11 of the 27 other live ones, and was the 46th registered.

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

421 studies on the registry are indexed under Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; 75 are open to participants now.

Browse Precursor T-Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

27 of the 51 studies in Precursor T-Cell Lymphoblastic Leukemia-Lymphoma with a site in China are open now. Recruiting first, the newest first:

21 more — sign in →

All 27 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 58 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 23 (40%) set no upper age limit and 30 (52%) stop at 75 or younger; 35 take children under 18; 1 takes healthy volunteers.

This study: 1 Year to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Precursor T-Cell Lymphoblastic Leukemia-Lymphoma with a site in China, or all of them as a file.
02

Study summary

This is a multi-center, open-label, non-randomized, phase 1/2 study of anti-CD5 CAR-T cell therapy in patients with CD5+ relapsed or refractory T-cell malignancies. A bayesian optimal interval (BOIN) 12 design will be used to explore the optimal biological dose (OBD) from starting dose level 1: 1×10\^6 (±20%) to dose level 2: 2×10\^6 (±20%) in three cohorts (autologous, previous-transplant-donor or newly matched donor-derived CD5 CAR T cells). If the manufactured cells are not sufficient to meet the preassigned standard dose criteria, patients will be given infusion at a low dose level of 5×10\^5 (±20%) /kg. The primary objective is to evaluate the safety and tolerability of CD5 CAR T cell therapy in subjects, determine the OBD and recommend phase 2 dose (RP2D) in phase 1, and evaluate the efficacy of CD5 CAR T cell therapy in phase 2. The primary endpoint is the type and incidence of dose-limiting toxicity (DLT) within 28 days, and the incidence and severity of adverse events (AEs) within 30 days after CD5 CAR T-cell infusion in phase 1, the best overall response (BOR) at 3 months (± 1 week) after CD5 CAR T-cell infusion in phase 2. A total number of 54 subjects will be enrolled.

Read the detailed description

详细描述

03

Conditions studied

  • T-Cell Acute Lymphocytic Leukemia
  • Acute Lymphoblastic Leukemia, in Relapse
  • Refractory Acute Lymphoblastic Leukemia
  • T-cell Malignancies
04

Who can participate

Ages eligible
1 Year to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Only patients who meet all the following criteria can be included:

1. Candidates with relapse or CD5+ T-cell , who have progressed after treatment with all standard therapies or been intolerant of standard care, have limited prognosis with currently available therapies and have no available curative treatment options (such as stem-cell transplantation (SCT) or chemotherapy); 2. For subjects who received autologous CD5 CAR T cells, the tumor burden in peripheral blood is less than 20%, and suspending anti-neoplastic treatment for more than 2 weeks; 3. Aged 1-70 years; 4. No severe allergy; 5. (ECOG) performance status 1 score 0 to 2; 6. Patients are expected to live for at least 60 days; 7. CD5+ on blasts in bone marrow (BM) or cerebrospinal fluid (CSF) and tumor tissues by flow cytometry and immunohistochemistry, respectively. (Positive rate >80% by flow cytometry with less than one log difference in mean fluorescence intensity from normal T cells, or positive rate >30% positive by immunohistochemistry); 8. Provide a signed before any screening procedure. Subjects who voluntarily participate in the study should have the ability to understand and sign the informed consent form and be willing to follow the study visit schedule and relevant study procedure, as specified in the protocol. Candidates aged 19-70 years need to be sufficiently conscious and able to sign the treatment consent form and voluntary consent form. Children candidates of 8-18 years old need to be sufficiently conscious and able to sign the treatment consent form and voluntary consent form and their legal guardian or patient advocate has also need to sign the treatment consent form and voluntary consent form, respectively. Children candidates of 1-7 can be recruited after the legal guardian or patient advocate has signed the treatment consent form and voluntary consent form; 9. Have available hematopoietic stem cell transplantation donor for the subject who received newly matched donor-derived CD5 CAR T cells, and is willing to perform SCT when CR is achieved.

-

Exclusion criteria

Exclusion Criteria:

Patients with at least one of the following conditions are excluded:

1. Impaired consciousness or intracranial hypertension; 2. Symptomatic congestive heart failure or severe cardiac arrhythmia; 3. Manifestations of severe respiratory system failure; 4. Co-existence with other ; 5. Disseminated intravascular coagulation; 6. Serum creatinine and/or blood urea nitrogen (BUN) ≥ 1.5-fold upper limit; 7. Sepsis or other uncontrollable infections; 8. Uncontrollable diabetes; 9. Serious mental illness; 10. Apparent and active intracranial lesions on cranial magnetic resonance imaging (MRI); 11. Underwent organ transplantation, excepting SCT; 12. Pregnant females; 13. Positive test for infectious hepatitis, acquired immune deficiency syndrome (AIDS) or syphilis; 14. Post-CAR SCT is not feasible in patients who plan to receive newly matched donor-derived CD5 CAR T cells; 15. Inability to collect peripheral blood mononuclear cells (PBMC) or no frozen PBMC available for CAR T cell manufacturing.

-

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
54 participants (estimated)

Study arms

  • Experimental
    Autologous CD5 CAR T-cells

    After a lymphodepleting regimen, the patients will receive autologous CD5 CAR T-cell infusion.

    Drug: Autologous CD5 CAR T-cells

  • Experimental
    Prior stem-cell transplantation (SCT) donor-derived CD5 CAR T-cells

    After a lymphodepleting regimen, the patients will receive prior SCT donor-derived CD5 CAR T-cell infusion.

    Drug: Previous stem-cell transplantation (SCT) donor-derived CD5 CAR T-cells

  • Experimental
    Newly matched donor-derived CD5 CAR T-cells

    After a lymphodepleting regimen, the patients will receive newly matched donor-derived CD5 CAR T-cell infusion

    Drug: Newly matched donor-derived CD5 CAR T-cells

Interventions

  • DrugAutologous CD5 CAR T-cells

    Peripheral blood mononuclear cells for the production of CD5 CAR T-cells from patients.

  • DrugPrevious stem-cell transplantation (SCT) donor-derived CD5 CAR T-cells

    Peripheral blood mononuclear cells for the production of CD5 CAR T cells are collected from previous SCT donors.

  • DrugNewly matched donor-derived CD5 CAR T-cells

    Peripheral blood mononuclear cells for the production of CD5 CAR T cells are collected from newly matched donors.

06

What researchers measure

Primary outcomes

  1. Phase 1-The incidence and type of dose-limiting toxicity (DLT)

    The number of patients experiencing dose-limiting toxicity (DLT) will be evaluated and the type of DLT will be recorded.

    Time frame: 28 days after CD5 CAR T cell infusion

  2. Phase 1-The incidence and severity of adverse events (AEs)

    The number of patients experiencing adverse events (AEs) and the severity of AEs will be evaluated.

    Time frame: 30 days after CD5 CAR T cell infusion

  3. Phase 2-Antitumor effect

    Assessment of best overall response (BOR) rate. BOR rate is the percentage of patients with the best overall response in complete response (CR), complete response with incomplete hematological recovery (CRi) or partial response (PR) based on the National Comprehensive Cancer Network (NCCN) Guidelines Version 3.2023 of Acute Lymphoblastic Leukemia.

    Time frame: 3 months (± 1 week) after CD5 CAR T infusion

Secondary outcomes

  1. Phase 1-Objective response rate (ORR)

    Objective response rate (ORR) is the percentage of subjects who have achieved CR, CRi or PR based on the National Comprehensive Cancer Network (NCCN) Guidelines Version 3.2023 of Acute Lymphoblastic Leukemia.

    Time frame: 30 days after CD5 CAR T cell infusion

  2. Phase 1-Pharmacokinetics of CD5 CAR T cells

    The proliferation and survival of CAR T cells will be measured by flow cytometry and quantitative polymerase chain reaction (qPCR).

    Time frame: Up to 2 years after CD5 CAR T cell infusion

  3. Phase 1-The incidence and severity of adverse events (AEs).

    The number of patients experiencing adverse events (AEs) and the severity of AEs will be evaluated.

    Time frame: From 30 days to 2 years after CD5 CAR T cell infusion

  4. Phase 1-Best overall response (BOR) rate.

    BOR rate is the percentage of patients with the best overall response in CR, CRi or PR based on the National Comprehensive Cancer Network (NCCN) Guidelines Version 3.2023 of Acute Lymphoblastic Leukemia.

    Time frame: 3 months (± 1 week) after CD5 CAR T cell infusion

  5. Phase 2-Objective response rate (ORR)

    Objective response rate (ORR) is the percentage of subjects who have achieved CR, CRi or PR based on the National Comprehensive Cancer Network (NCCN) Guidelines Version 3.2023 of Acute Lymphoblastic Leukemia.

    Time frame: 1 months and 3 months after CD5 CAR T cell infusion

  6. Phase 2- The incidence and severity of AEs

    The number of patients experiencing adverse events (AEs) and the severity of AEs will be evaluated.

    Time frame: Up to 2 years

  7. Phase 2- Progression free survival (PFS)

    Progression-free survival (PFS) is defined as the time from the initial CD5 CAR T cell infusion to the date of progression or death for any cause.

    Time frame: Up to 2 years

  8. Phase 2- Overall survival (OS).

    Overall survival (OS) is defined the time from the initial CD5 CAR T cell infusion to death for any cause.

    Time frame: Up to 2 years

07

Study locations

3 of 4 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2025 (actual). Primary completion is estimated for Dec 2026, 17 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2025
First posted
Jul 17, 2025
StartActual
Jul 9, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Nov 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07070323
Lead sponsor
Beijing GoBroad Hospital
Collaborators
The General Hospital of Western Theater Command, Zhaxin Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, Shanghai Liquan Hospital, Central People's Hospital of Zhanjiang, First Affiliated Hospital of Guangxi Medical University
Responsible party
Jing Pan (Director of Dept of Hemato-Oncology and Immunotherapy, Beijing GoBroad Hospital) — Principal investigator
First posted
Jul 17, 2025
Start date
Jul 9, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Nov 26, 2025

Study contacts

Shaocong Miao
Contact
miaosc@gobroadhealthcare.com
86+18831006667

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion